Generated by AI
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious vascular and ischemic diseases. Its current pipeline is centered on DM199, a recombinant form of human tissue kallikrein-1 being studied for acute ischemic stroke, preeclampsia, fetal growth restriction, and other conditions linked to impaired blood flow. The company also advances DM300, a recombinant human ulinastatin candidate in preclinical development for inflammatory disorders. DiaMedica Therapeutics serves the neuroscience, women’s health, renal, and inflammatory disease areas through therapies designed to address significant unmet medical needs. Headquartered in Minneapolis, Minnesota, DiaMedica Therapeutics Inc. operates as a specialized biotech platform focused on recombinant protein-based drug development.
Website301 Carlson Parkway
Minneapolis, MN, 55305
United States
The latest articles about DMAC.
Analyst rates DiaMedica Therapeutics a Buy: ReMEDy2's Q1 2027 interim could prompt a stop on strong efficacy; Nov.
Summary of Sep 8's posts. Generated by AI.
Summary of Jul 7's posts. Generated by AI.
Summary of Jul 7's posts. Generated by AI.
Investors talking about DMAC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.